Silk Good call. afternoon for and Road thank earnings joining Caroline. Thanks, third you everyone quarter for us Medical's
Buchanan, Joining Chief Financial and me Officer Lucas Operating is our Officer. Chief
commitment to a of growth serve disease. are prevention third to of $XX.X underlying of and year-over-year. XX% severity steadfast total team's results Our We quarter reflecting the our million, artery testament achieved revenues carotid
in line performance was for XX% total the a by procedures top driven in quarter. XXXX approximately Our of growth
team's the recently XX,XXX procedure drive our trends, recent COVID-XX potential trends testament fourth about to the cumulative and proud we cautiously encouraging and have That incredibly acknowledging demand, underlying a to being these also but optimistic market volumes and recognizing opportunity. resurgence. milestone, negative said, of are remain and the crossed strength we underlying With quarter, procedures the the very impacts
we've been to of course strengthening year, the ability Over growth. long-term the drive our
brighter are commercial recent bright. new indeed We future our the launch in is of campaign, R&D Road of featuring and expansion Silk meaningfully team, website investing our of our initiatives, the
leadership our positioning also are structure ahead. and organizational We for growth
for efforts by international commercial launches future product safe the of to role spearheading success have expansions, position newly gearing our year, commercial the of States TCAR Chief in legal he Davis our earlier in announced Andy in a across driving Commercial strategies. continues and Andy Officer. created we while adoption monumental the As is United up
where Officer. scientific new and leadership leading we our and our our teams. him and both am a and solving of he have Vice track excited is tomorrow. strategic Lucas I and Chief operational about of property advancing COO, two Financial strong Silk has initiatives unmet who organization Road make Lucas passion President He Executive ideal Bill our record And R&D. identifying as role decades has Operating Bill while Chief our leadership to portfolio. Bill pleased in brings for announce, will for and an of also responsible pursue to as our of proven our clinical needs are and R&D expanded pipelines, to the has We deep growth Whealon to business instrumental knowledge development scale skills maintaining Officer the excellence. finally, innovative addition expanding as today Buchanan, promotion intellectual a be now
untapped beginning to significant now the population, the further through that we patient U.S. commercial coverage at on on making risk Commercial we surgical large surgical developing with year, for and of our pipeline development. outlined execution, XXXX are three strategy high physician market label Turning and for strategic in penetration progress drive execution, to risk all standard opportunity the focused the TCAR our Starting expansion for three; utilization. initiatives we remain patients increased first U.S.
accounts to base to have we to expanding with XXXX and continued team active trained While our end add on of sales XX to and territories, our XX talented track remain hospital physicians, commercial territories.
ways physicians COVID-XX that of job also done new training to environment. and the an adjust the realities has team innovative Our in excellent
quite on training pivoted in our training the physicians strong. quarter's about in methods, quarter. third are that Demand we have progress new training we to QX talked we pleased TCAR last remains call, with and for successfully Our
more high impact peer validate the journals past care X Study Surgery of reviewed clinical further validation reach Annals of And over Surveillance continuum across of data other Association’s long-term factor reaches Collectively, journal and TCAR papers regulators, now, were societies, published of and to major physicians it datasets represent growth. patients the also benefits the broad this this ever-growing a second clarity in worth treating further just in shifting in strategy July. our TCAR data stakeholders on clinical and Stroke referring These surgical continue Project of evidence-base September enable our risk FDA. with our base our business, providing a and As standard patients, platform ROADSTER key regulatory stroke and including ongoing we as In on medical the progress of in the in this we for Heart payers, discussions the tailwind to meaningful American our reimbursement these key quarter. X,XXX critical ongoing stakeholders. by honored to publication recent make the for priority, is
targeting strategy detail. more disclosed, been previously our the As end this we area this in in to discuss have year of
of of the process the Surgery with substantial FDA, through taking working While time. the more nothing and our the CMS has changed it of assessment Vascular Society strategy, simply in is
end disclosure result, of likely year. a to after the occur is strategy As the of our
Our to an coverage and and path that ultimately on goal path. remain Medicare reach adoption obtain all has been to just not optimal also but forward we expanded label, along FDA
Finally, and ischemic our is neuro-protection, on we focused pipeline just continued consider and product on We stroke. meaningful priority development, in also have development. not progress transcarotid third strategic made for access in acute but ourselves experts TCAR,
program for We clinical neurovascular regulatory next activities and are to into expecting year. move our
terms believe are acute we long-term transcarotid detail. our our the opportunities continuing with are will recent usher to of our initiatives, treatment, I stroke prevention Lucas been than that, the ever. we in and on now financials stroke call and to more review brighter turn our over progress about With in for has unmet remain While we potential excited patient in and therapies significant In stroke thrombectomy a to in years, achieved in much acute needs summary, are new in outcomes, paradigm.
